Our analysis suggests that paclitaxel and bromocriptine, which dock with nucleocapsid and Nsp4 proteins can also effectively bind to c-Fos and thereby would be beneficial in inhibiting SARS-CoV2, as well as in alleviating lung injury observed in COVID-19 patients. Here, FOS is linked to COVID-19.